Coherus Oncology (CHRS) EBITDA Margin Growth (5y) (2019 - 2026)
Coherus Oncology (CHRS) EBITDA Margin Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,212.00 |
| Dec 31, 2025 | -37,477.00 |
| Sep 30, 2025 | -41,283.00 |
| Jun 30, 2025 | -49,173.00 |
| Mar 31, 2025 | -63,308.00 |
| Dec 31, 2024 | -62,324.00 |
| Sep 30, 2024 | -82,064.00 |
| Jun 30, 2024 | -41,782.00 |
| Mar 31, 2024 | -289,230.00 |
| Jun 30, 2022 | 397,240.00 |
| Mar 31, 2022 | 4.48 Mn |
| Dec 31, 2021 | 864,988.00 |
| Sep 30, 2021 | -9,171.00 |
| Jun 30, 2021 | 41,838.00 |
| Mar 31, 2021 | 31,913.00 |
| Dec 31, 2020 | 52,681.00 |
| Sep 30, 2020 | 102,337.00 |
| Jun 30, 2020 | 90,591.00 |
| Mar 31, 2020 | 66,767.00 |
| Dec 31, 2019 | 44,541.00 |